June 11, 2020

Acquisitions of companies involved in the medical devices business fall under the Italian foreign investment control

More than 2 months ago the Italian Government issued certain measures[1] with the purpose of expanding its power to veto or impose conditions on acquisitions of, or other transactions involving, Italian targets operating in certain strategic sectors.

Recently[2] the abovementioned measures have been converted into Law and have been partially amended in the conversion process.

One of the amendments consists of specifying that, on a temporary basis (i.e. until the issuance of the relevant implementing decrees), acquisitions of controlling stakes in Italian target companies operating in business of production, import and wholesale distribution of medical devices, medical/surgical devices and personal protective devices must be notified to the Italian Government under the foreign investment control regime.

We note that the same clarification has not been made with respect to those provisions (included in the same set of measures) aimed specifically at hindering the COVID-19 emergency which expand/strengthen significantly the Italian Government’s control power (providing duties to notify acquisitions of controlling stakes also by EU acquirors, etc.) until December 31, 2020.

For more information please see our article on “The Expansion of Italian Foreign Investment Control in the COVID-19 era” available at this link.

[1] Articles 15 and following of Law Decree no. 23 of April 8, 2020.

[2] By means of Law no. 40 of June 5, 2020.

< Back to blog
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the life sciences and healthcare industry.
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and venture capital transactions.

March 20, 2023
Today, Regulation (EU) 2023/607 extending the transitional provisions for the placing on the market and putting into service of certain medical devices and in vitro diagnostic medical device...
January 31, 2023
Clinical trials: Ministry of Health signed off on decrees that (i) reorganize ethics committees and coordinate their activities, (ii) determine the single tariff for the authorization proced...
December 19, 2022
On 13 December 2022, EMA, European Commission and HMA jointly adopted a recommendation paper on the introduction of decentralised elements in the conduct of Clinical Trials in the EU/EEA
September 21, 2022
Payback for medical devices: Decree quantifying the exceeding of the expenditure ceiling for medical devices at national and regional level for the years 2015, 2016, 2017 and 2018 published ...
September 1, 2022
The 2021 annual law for market and competition addressing, as to the healthcare sector, reimbursement of drugs, intermediate distribution, patent linkage and institutional accreditation of p...
Search by...
Follow us on
Follow us on